Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.45 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14499023 | 0.94 | TAAR1 (0.53) | MAOBTAAR1HTTSMN1; SMN2SLC6A4 | |
| SCHEMBL14263251 | 0.84 | CALM1 (0.55) | MAOBTAAR1HTTSMN1; SMN2SLC6A4 | |
| SCHEMBL14263159 | 0.83 | NQO1 (0.47) | SMN1; SMN2SIGMAR1 | |
| SCHEMBL14263158 | 0.81 | KCNH2 (0.44) | TAAR1ALDH1A1IDO1 | |
| SCHEMBL14263233 | 0.81 | TAAR1 (0.42) | MAOBTAAR1 | |
| SCHEMBL14263242 | 0.80 | MAOB (0.48) | MAOBTAAR1AOC3 | |
| SCHEMBL14274195 | 0.80 | CYP4F2 (0.38) | MAOB | |
| SCHEMBL29143222 | 0.78 | TAAR1 (0.52) | MAOBTAAR1HTTSMN1; SMN2SLC6A4 | |
| SCHEMBL10569081 | 0.77 | MAOB (0.70) | MAOBTAAR1AOC3CALM1SIGMAR1 | |
| SCHEMBL14263243 | 0.76 | MAOB (0.53) | MAOBTAAR1ALDH1A1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | MAOB 2920/4885TAAR1 596/4885HTT 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.